gilead sciences ltd
gilead sciences ltd Company Information
Company Number
02543818
Website
www.gilead.comRegistered Address
280 high holborn, london, WC1V 7EE
Industry
Wholesale of pharmaceutical goods
Telephone
02036814500
Next Accounts Due
September 2024
Group Structure
View All
Shareholders
gilead sciences ireland unlimited company 100%
gilead sciences ltd Estimated Valuation
Pomanda estimates the enterprise value of GILEAD SCIENCES LTD at £364.5m based on a Turnover of £253.4m and 1.44x industry multiple (adjusted for size and gross margin).
gilead sciences ltd Estimated Valuation
Pomanda estimates the enterprise value of GILEAD SCIENCES LTD at £116.3m based on an EBITDA of £11.7m and a 9.95x industry multiple (adjusted for size and gross margin).
gilead sciences ltd Estimated Valuation
Pomanda estimates the enterprise value of GILEAD SCIENCES LTD at £49.5m based on Net Assets of £24.3m and 2.03x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Gilead Sciences Ltd Overview
Gilead Sciences Ltd is a live company located in london, WC1V 7EE with a Companies House number of 02543818. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in September 1990, it's largest shareholder is gilead sciences ireland unlimited company with a 100% stake. Gilead Sciences Ltd is a mature, mega sized company, Pomanda has estimated its turnover at £253.4m with low growth in recent years.
Upgrade for unlimited company reports & a free credit check
Gilead Sciences Ltd Health Check
Pomanda's financial health check has awarded Gilead Sciences Ltd a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 4 areas for improvement. Company Health Check FAQs
5 Strong
3 Regular
4 Weak
Size
annual sales of £253.4m, make it larger than the average company (£26.1m)
£253.4m - Gilead Sciences Ltd
£26.1m - Industry AVG
Growth
3 year (CAGR) sales growth of 2%, show it is growing at a slower rate (4.3%)
2% - Gilead Sciences Ltd
4.3% - Industry AVG
Production
with a gross margin of 29.5%, this company has a comparable cost of product (26.2%)
29.5% - Gilead Sciences Ltd
26.2% - Industry AVG
Profitability
an operating margin of 4.1% make it as profitable than the average company (4%)
4.1% - Gilead Sciences Ltd
4% - Industry AVG
Employees
with 184 employees, this is above the industry average (40)
184 - Gilead Sciences Ltd
40 - Industry AVG
Pay Structure
on an average salary of £186.7k, the company has a higher pay structure (£72.3k)
£186.7k - Gilead Sciences Ltd
£72.3k - Industry AVG
Efficiency
resulting in sales per employee of £1.4m, this is more efficient (£636.6k)
£1.4m - Gilead Sciences Ltd
£636.6k - Industry AVG
Debtor Days
it gets paid by customers after 50 days, this is near the average (59 days)
50 days - Gilead Sciences Ltd
59 days - Industry AVG
Creditor Days
its suppliers are paid after 5 days, this is quicker than average (30 days)
5 days - Gilead Sciences Ltd
30 days - Industry AVG
Stock Days
it holds stock equivalent to 32 days, this is less than average (64 days)
32 days - Gilead Sciences Ltd
64 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 17 weeks, this is more cash available to meet short term requirements (11 weeks)
17 weeks - Gilead Sciences Ltd
11 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 81.5%, this is a higher level of debt than the average (56.3%)
81.5% - Gilead Sciences Ltd
56.3% - Industry AVG
GILEAD SCIENCES LTD financials
Gilead Sciences Ltd's latest turnover from December 2022 is £253.4 million and the company has net assets of £24.3 million. According to their latest financial statements, Gilead Sciences Ltd has 184 employees and maintains cash reserves of £35.6 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 253,431,000 | 287,435,000 | 270,364,000 | 235,731,000 | 326,316,000 | 438,117,000 | 511,646,000 | 451,192,000 | 357,303,000 | 300,128,000 | 283,395,000 | 272,261,000 | 248,493,000 | 209,936,000 |
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost Of Sales | 178,649,000 | 212,903,000 | 202,536,000 | 179,069,000 | 270,326,000 | 361,754,000 | 437,232,000 | 381,617,000 | 304,657,000 | 260,687,000 | 250,980,000 | 243,269,000 | 223,457,000 | 184,216,000 |
| Gross Profit | 74,782,000 | 74,532,000 | 67,828,000 | 56,662,000 | 55,990,000 | 76,363,000 | 74,414,000 | 69,575,000 | 52,646,000 | 39,441,000 | 32,415,000 | 28,992,000 | 25,036,000 | 25,720,000 |
| Admin Expenses | 64,521,000 | 63,365,000 | 57,231,000 | 47,581,000 | 43,635,000 | 60,024,000 | 57,061,000 | 54,569,000 | 44,507,000 | 34,235,000 | 28,181,000 | 23,005,000 | 21,411,000 | 19,349,000 |
| Operating Profit | 10,261,000 | 11,167,000 | 10,597,000 | 9,081,000 | 12,355,000 | 16,339,000 | 17,353,000 | 15,006,000 | 8,139,000 | 5,206,000 | 4,234,000 | 5,987,000 | 3,625,000 | 6,371,000 |
| Interest Payable | 69,000 | 106,000 | 195,000 | 248,000 | 11,000 | 352,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,000 |
| Interest Receivable | 1,008,000 | 33,000 | 101,000 | 482,000 | 553,000 | 137,000 | 185,000 | 126,000 | 87,000 | 37,000 | 37,000 | 15,000 | 0 | 35,000 |
| Pre-Tax Profit | 11,200,000 | 11,094,000 | 10,503,000 | 9,315,000 | 12,897,000 | 16,124,000 | 17,538,000 | 15,132,000 | 8,226,000 | 5,243,000 | 4,271,000 | 6,002,000 | 3,625,000 | 6,404,000 |
| Tax | -1,940,000 | -1,930,000 | -2,225,000 | -1,995,000 | -2,613,000 | -7,722,000 | -3,648,000 | -3,188,000 | -1,762,000 | -1,056,000 | -563,000 | -1,698,000 | -637,000 | -1,815,000 |
| Profit After Tax | 9,260,000 | 9,164,000 | 8,278,000 | 7,320,000 | 10,284,000 | 8,402,000 | 13,890,000 | 11,944,000 | 6,464,000 | 4,187,000 | 3,708,000 | 4,304,000 | 2,988,000 | 4,589,000 |
| Dividends Paid | 0 | 0 | 10,284,000 | 44,887,000 | 0 | 0 | 0 | 0 | 0 | 0 | 5,407,000 | 3,498,000 | 9,309,000 | 0 |
| Retained Profit | 9,260,000 | 9,164,000 | -2,006,000 | -37,567,000 | 10,284,000 | 8,402,000 | 13,890,000 | 11,944,000 | 6,464,000 | 4,187,000 | -1,699,000 | 806,000 | -6,321,000 | 4,589,000 |
| Employee Costs | 34,346,000 | 32,860,000 | 31,082,000 | 24,225,000 | 21,349,000 | 20,212,000 | 19,762,000 | 19,281,000 | 15,184,000 | 12,723,000 | 10,361,000 | 8,696,000 | 7,510,000 | 6,669,000 |
| Number Of Employees | 184 | 178 | 170 | 146 | 132 | 132 | 131 | 127 | 111 | 94 | 86 | 82 | 79 | 81 |
| EBITDA* | 11,682,000 | 12,578,000 | 12,025,000 | 10,527,000 | 12,701,000 | 16,784,000 | 17,815,000 | 15,415,000 | 8,177,000 | 5,215,000 | 4,256,000 | 6,010,000 | 3,655,000 | 6,404,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 2,048,000 | 3,395,000 | 4,754,000 | 5,971,000 | 1,519,000 | 1,865,000 | 2,310,000 | 2,662,000 | 2,061,000 | 75,000 | 20,000 | 16,000 | 39,000 | 26,000 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 2,399,000 | 1,554,000 | 1,016,000 | 835,000 | 720,000 | 814,000 | 746,000 | 1,040,000 | 1,616,000 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 4,447,000 | 4,949,000 | 5,770,000 | 6,806,000 | 2,239,000 | 2,679,000 | 3,056,000 | 3,702,000 | 3,677,000 | 75,000 | 20,000 | 16,000 | 39,000 | 26,000 |
| Stock & work in progress | 15,992,000 | 16,264,000 | 33,873,000 | 24,608,000 | 1,850,000 | 2,409,000 | 2,861,000 | 6,161,000 | 3,270,000 | 1,659,000 | 1,490,000 | 0 | 0 | 0 |
| Trade Debtors | 35,090,000 | 23,881,000 | 62,129,000 | 20,800,000 | 13,756,000 | 25,855,000 | 50,895,000 | 71,230,000 | 35,684,000 | 31,804,000 | 28,968,000 | 38,916,000 | 27,860,000 | 23,102,000 |
| Group Debtors | 311,000 | 492,000 | 362,000 | 664,000 | 346,000 | 695,000 | 296,000 | 2,410,000 | 45,000 | 67,000 | 238,000 | 13,000 | 37,000 | 848,000 |
| Misc Debtors | 40,007,000 | 35,091,000 | 28,892,000 | 28,533,000 | 18,064,000 | 2,128,000 | 5,443,000 | 1,720,000 | 2,945,000 | 2,288,000 | 1,285,000 | 537,000 | 1,641,000 | 777,000 |
| Cash | 35,605,000 | 129,251,000 | 26,265,000 | 50,850,000 | 146,672,000 | 75,557,000 | 46,565,000 | 23,296,000 | 18,514,000 | 11,672,000 | 8,498,000 | 12,699,000 | 6,162,000 | 7,842,000 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 127,005,000 | 204,979,000 | 151,521,000 | 125,455,000 | 180,688,000 | 106,644,000 | 106,060,000 | 104,817,000 | 60,458,000 | 47,490,000 | 40,479,000 | 52,165,000 | 35,700,000 | 32,569,000 |
| total assets | 131,452,000 | 209,928,000 | 157,291,000 | 132,261,000 | 182,927,000 | 109,323,000 | 109,116,000 | 108,519,000 | 64,135,000 | 47,565,000 | 40,499,000 | 52,181,000 | 35,739,000 | 32,595,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 2,559,000 | 3,615,000 | 1,953,000 | 1,143,000 | 1,440,000 | 1,274,000 | 820,000 | 1,295,000 | 1,182,000 | 462,000 | 832,000 | 776,000 | 267,000 | 714,000 |
| Group/Directors Accounts | 22,722,000 | 69,742,000 | 37,033,000 | 11,232,000 | 24,348,000 | 14,682,000 | 20,098,000 | 3,016,000 | 13,836,000 | 18,255,000 | 18,382,000 | 26,921,000 | 18,247,000 | 11,708,000 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 1,607,000 | 1,543,000 | 1,510,000 | 1,393,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 78,506,000 | 70,042,000 | 64,755,000 | 67,675,000 | 78,934,000 | 28,784,000 | 35,420,000 | 68,361,000 | 27,699,000 | 17,501,000 | 16,088,000 | 19,066,000 | 13,718,000 | 10,651,000 |
| total current liabilities | 105,394,000 | 144,942,000 | 105,251,000 | 81,443,000 | 104,722,000 | 44,740,000 | 56,338,000 | 72,672,000 | 42,717,000 | 36,218,000 | 35,302,000 | 46,763,000 | 32,232,000 | 23,073,000 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 324,000 | 1,874,000 | 3,405,000 | 4,711,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 233,000 | 1,141,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 1,417,000 | 973,000 | 694,000 | 644,000 | 581,000 | 662,000 | 638,000 | 744,000 | 1,048,000 | 947,000 | 103,000 | 11,000 | 9,000 | 213,000 |
| total long term liabilities | 1,741,000 | 2,847,000 | 4,332,000 | 6,496,000 | 581,000 | 662,000 | 638,000 | 744,000 | 1,048,000 | 947,000 | 103,000 | 11,000 | 9,000 | 213,000 |
| total liabilities | 107,135,000 | 147,789,000 | 109,583,000 | 87,939,000 | 105,303,000 | 45,402,000 | 56,976,000 | 73,416,000 | 43,765,000 | 37,165,000 | 35,405,000 | 46,774,000 | 32,241,000 | 23,286,000 |
| net assets | 24,317,000 | 62,139,000 | 47,708,000 | 44,322,000 | 77,624,000 | 63,921,000 | 52,140,000 | 35,103,000 | 20,370,000 | 10,400,000 | 5,094,000 | 5,407,000 | 3,498,000 | 9,309,000 |
| total shareholders funds | 24,317,000 | 62,139,000 | 47,708,000 | 44,322,000 | 77,624,000 | 63,921,000 | 52,140,000 | 35,103,000 | 20,370,000 | 10,400,000 | 5,094,000 | 5,407,000 | 3,498,000 | 9,309,000 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | 10,261,000 | 11,167,000 | 10,597,000 | 9,081,000 | 12,355,000 | 16,339,000 | 17,353,000 | 15,006,000 | 8,139,000 | 5,206,000 | 4,234,000 | 5,987,000 | 3,625,000 | 6,371,000 |
| Depreciation | 1,421,000 | 1,411,000 | 1,428,000 | 1,446,000 | 346,000 | 445,000 | 462,000 | 409,000 | 38,000 | 9,000 | 22,000 | 23,000 | 30,000 | 33,000 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | -1,940,000 | -1,930,000 | -2,225,000 | -1,995,000 | -2,613,000 | -7,722,000 | -3,648,000 | -3,188,000 | -1,762,000 | -1,056,000 | -563,000 | -1,698,000 | -637,000 | -1,815,000 |
| Stock | -272,000 | -17,609,000 | 9,265,000 | 22,758,000 | -559,000 | -452,000 | -3,300,000 | 2,891,000 | 1,611,000 | 169,000 | 1,490,000 | 0 | 0 | 0 |
| Debtors | 16,789,000 | -31,381,000 | 41,567,000 | 17,946,000 | 3,394,000 | -27,888,000 | -19,020,000 | 36,110,000 | 6,131,000 | 3,668,000 | -8,975,000 | 9,928,000 | 4,811,000 | 24,727,000 |
| Creditors | -1,056,000 | 1,662,000 | 810,000 | -297,000 | 166,000 | 454,000 | -475,000 | 113,000 | 720,000 | -370,000 | 56,000 | 509,000 | -447,000 | 714,000 |
| Accruals and Deferred Income | 8,464,000 | 5,287,000 | -2,920,000 | -11,259,000 | 50,150,000 | -6,636,000 | -32,941,000 | 40,662,000 | 10,198,000 | 1,413,000 | -2,978,000 | 5,348,000 | 3,067,000 | 10,651,000 |
| Deferred Taxes & Provisions | 444,000 | 279,000 | 50,000 | 63,000 | -81,000 | 24,000 | -106,000 | -304,000 | 101,000 | 844,000 | 92,000 | 2,000 | -204,000 | 213,000 |
| Cash flow from operations | 1,077,000 | 66,866,000 | -43,092,000 | -43,665,000 | 57,488,000 | 31,244,000 | 2,965,000 | 13,697,000 | 9,692,000 | 2,209,000 | 8,348,000 | 243,000 | 623,000 | -8,560,000 |
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | -47,020,000 | 32,709,000 | 25,801,000 | -13,116,000 | 9,666,000 | -5,416,000 | 17,082,000 | -10,820,000 | -4,419,000 | -127,000 | -8,539,000 | 8,674,000 | 6,539,000 | 11,708,000 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | -1,486,000 | -1,498,000 | -1,189,000 | 6,104,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | -233,000 | -908,000 | 1,141,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | 939,000 | -73,000 | -94,000 | 234,000 | 542,000 | -215,000 | 185,000 | 126,000 | 87,000 | 37,000 | 37,000 | 15,000 | 0 | 33,000 |
| cash flow from financing | -94,649,000 | 36,172,000 | 29,002,000 | -1,372,000 | 13,627,000 | -2,252,000 | 20,414,000 | -7,905,000 | -826,000 | 1,029,000 | -7,116,000 | 9,792,000 | 7,049,000 | 16,461,000 |
| cash and cash equivalents | ||||||||||||||
| cash | -93,646,000 | 102,986,000 | -24,585,000 | -95,822,000 | 71,115,000 | 28,992,000 | 23,269,000 | 4,782,000 | 6,842,000 | 3,174,000 | -4,201,000 | 6,537,000 | -1,680,000 | 7,842,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -93,646,000 | 102,986,000 | -24,585,000 | -95,822,000 | 71,115,000 | 28,992,000 | 23,269,000 | 4,782,000 | 6,842,000 | 3,174,000 | -4,201,000 | 6,537,000 | -1,680,000 | 7,842,000 |
gilead sciences ltd Credit Report and Business Information
Gilead Sciences Ltd Competitor Analysis
Perform a competitor analysis for gilead sciences ltd by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other mega companies, companies in WC1V area or any other competitors across 12 key performance metrics.
gilead sciences ltd Ownership
GILEAD SCIENCES LTD group structure
Gilead Sciences Ltd has no subsidiary companies.
Ultimate parent company
GILEAD SCIENCES INC
#0135210
GILEAD SCIENCES IRELAND UNLIMITED COMPAN
IE259755
2 parents
GILEAD SCIENCES LTD
02543818
gilead sciences ltd directors
Gilead Sciences Ltd currently has 4 directors. The longest serving directors include Mr Andrew Dickinson (Oct 2019) and Mr John Jorden (Jun 2023).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Andrew Dickinson | United Kingdom | 54 years | Oct 2019 | - | Director |
| Mr John Jorden | United Kingdom | 40 years | Jun 2023 | - | Director |
| Mr Hans Stucker | 51 years | Jun 2023 | - | Director | |
| Ms Janet Dorling | 50 years | Jun 2023 | - | Director |
P&L
December 2022turnover
253.4m
-12%
operating profit
10.3m
-8%
gross margin
29.6%
+13.8%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
24.3m
-0.61%
total assets
131.5m
-0.37%
cash
35.6m
-0.72%
net assets
Total assets minus all liabilities
gilead sciences ltd company details
company number
02543818
Type
Private limited with Share Capital
industry
46460 - Wholesale of pharmaceutical goods
incorporation date
September 1990
age
34
incorporated
UK
accounts
Full Accounts
ultimate parent company
previous names
nexstar pharmaceuticals limited (January 2001)
vestar limited (October 1995)
last accounts submitted
December 2022
address
280 high holborn, london, WC1V 7EE
accountant
-
auditor
ERNST & YOUNG
gilead sciences ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to gilead sciences ltd.
gilead sciences ltd Companies House Filings - See Documents
| date | description | view/download |
|---|
